Ublituximab. Good results as of last November
Ublituximab. Good results as of last November
https://eu.eventscloud.com/file_uploads ... ubanks.pdf
Conclusions:
- Annualized Relapse Rate (ARR) of 0.07 was observed at Week 48, with 93% of subjects being relapse free.
- 74% of subjects fulfilled the criteria for NEDA.
- Median B cell depletion was >99% at the primary analysis point of Week 4 (n=48), and maintained at Week 24 and Week 48.
- No T1 Gd-enhancing lesions detected in any subjects at Week 24 or 48 (100% reduction; p=0.003).
- Subjects saw 10.6% reduction in total T2 lesion volume from baseline to Week 48 (p=0.002).
- Ublituximab was well tolerated and the most frequent AEs (all Grade 1 or 2) were Infusion Related Reactions (IRRs).
- No subjects discontinued due to an AE related to ublituximab.
- A rapid infusion time, as low as one hour, of 450mg, was well tolerated, produced high levels of B cell depletion and
- is now being studied in the Phase 3 ULTIMATE trials in MS.
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2103 Views
-
Last post by frodo
Thu Apr 25, 2019 5:08 am
-
- 2 Replies
- 1323 Views
-
Last post by zen2010
Fri Mar 08, 2019 1:17 am
-
- 0 Replies
- 520 Views
-
Last post by gristy56
Sat Apr 20, 2019 1:33 am
-
- 2 Replies
- 993 Views
-
Last post by jimmylegs
Fri Mar 08, 2019 6:02 pm
-
-
Ketogenic diet good for SPMS (at least some cases)
by frodo » Mon Aug 26, 2019 12:05 am » in General Discussion - 0 Replies
- 631 Views
-
Last post by frodo
Mon Aug 26, 2019 12:05 am
-
-
- 3 Replies
- 1625 Views
-
Last post by NHE
Fri Mar 01, 2019 2:22 am
-
- 2 Replies
- 1202 Views
-
Last post by Scott1
Wed Jul 17, 2019 12:28 am
-
- 3 Replies
- 1253 Views
-
Last post by NHE
Sun Sep 29, 2019 11:10 pm